Supranuclear Palsy, Progressive: Clinical Trials

9 trials for Supranuclear Palsy, Progressive, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 terminated, 1 recruiting. 9 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Completed 6, Terminated 2, Recruiting 1
Phase 23Completed 3

Follow Supranuclear Palsy, Progressive: new trials by email Literature Review of Supranuclear Palsy, Progressive trials Research Report on Supranuclear Palsy, Progressive

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NIO752, Placebo - Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Phase 3RecruitingNovartis Pharmaceuticals3002026-06-032026-10-15
AMX0035 and Progressive Supranuclear Palsy
AMX0035, Placebo - Progressive Supranuclear Palsy, PSP
Phase 2 / Phase 3CompletedAmylyx Pharmaceuticals Inc.1392023-12-212026-04-30
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
DaTSCAN™ Ioflupane (123I) Injection - Parkinsonian Syndrome, Parkinson Disease(PD)
Phase 3CompletedGE Healthcare1722020-06-282023-10-16
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg - Dementia-related Psychosis
Phase 3CompletedACADIA Pharmaceuticals Inc.3922017-09-272021-06-21
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy
Rivastigmine, Placebo - Progressive Supranuclear Palsy (PSP)
Phase 3CompletedAssistance Publique Hopitaux De Marseille1062016-07-262023-07-20
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Davunetide, Placebo - Progressive Supranuclear Palsy
Phase 2 / Phase 3CompletedAllon Therapeutics3132010-10-012013-01-17
Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy
Rasagiline, Sugar pill - Progressive Supranuclear Palsy
Phase 3TerminatedProf. Dr. Stefan Lorenzl442010-01-012013-04-24
Effects of Coenzyme Q10 in PSP and CBD
CoQ10 - Progressive Supranuclear Palsy, Neurological Disorders
Phase 2 / Phase 3CompletedLahey Clinic2004-01-012018-06-15
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
Riluzole - Multiple System Atrophy, Progressive Supranuclear Palsy
Phase 3TerminatedKing's College London8002000-04-012005-12-15

Narrower conditions

Multiple System Atrophy (2)  ·  Alzheimer Disease (1)  ·  Corticobasal Degeneration (1)  ·  Delusions (1)  ·  Dementia (1)  ·  Dementia, Vascular (1)  ·  Essential Tremor (1)  ·  Hallucinations (1)  ·  Lewy Body Disease (1)  ·  Nervous System Diseases (1)  ·  Neurodegenerative Diseases (1)  ·  Parkinson Disease (1)  ·  Parkinsonian Disorders (1)  ·  Pick Disease of the Brain (1)

Broader conditions

Basal Ganglia Diseases (9)  ·  Brain Diseases (9)  ·  Central Nervous System Diseases (9)  ·  Cranial Nerve Diseases (9)  ·  Eye Diseases (9)  ·  Movement Disorders (9)  ·  Neurologic Manifestations (9)  ·  Ocular Motility Disorders (9)  ·  Ophthalmoplegia (9)  ·  Paralysis (9)  ·  Pathological Conditions, Signs and Symptoms (9)  ·  Signs and Symptoms (9)  ·  Tauopathies (9)  ·  Nervous System Diseases (8)  ·  Neurodegenerative Diseases (8)

Interventions

Injections (1)  ·  Iodine-123 (1)  ·  Riluzole (1)  ·  Rivastigmine (1)  ·  Sugars (1)  ·  coenzyme Q10 (1)  ·  davunetide (1)  ·  ioflupane (1)  ·  pimavanserin (1)  ·  rasagiline (1)  ·  sodium phenylbutyrate and taurursodiol (1)

Sponsors

ACADIA Pharmaceuticals Inc. (1)  ·  Allon Therapeutics (1)  ·  Amylyx Pharmaceuticals Inc. (1)  ·  Assistance Publique Hopitaux De Marseille (1)  ·  GE Healthcare (1)  ·  King's College London (1)  ·  Lahey Clinic (1)  ·  Novartis Pharmaceuticals (1)  ·  Prof. Dr. Stefan Lorenzl (1)

Countries

France (5)  ·  Germany (5)  ·  United States (5)  ·  United Kingdom (4)  ·  Italy (3)  ·  Spain (3)  ·  Australia (2)  ·  China (2)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Chile (1)  ·  Czechia (1)  ·  Japan (1)  ·  Netherlands (1)

Top investigators

Adam Boxer, M.D., PhD. (1)  ·  Diana Apetauerova, MD (1)  ·  Peter N Leigh, PhD FRCP (1)  ·  Stefan Lorenzl, PD Dr. (1)

Results publications

PMID 19029129, PMID 19771175, PMID 21386111, PMID 21829612, PMID 24873720, PMID 28436538, PMID 34289275, PMID 34934801, PMID 38825840, PMID 41286676

NIH funding

2008 (1), 2016 (1), 2017 (1)